Perlman Department of Dermatology at NYU Grossman School of Medicine ... “The discovery of cell-free, circulating tumor DNA (ctDNA) as a direct, albeit imperfect, measurement of tumor ...

A review now published in the Journal of Experimental & Clinical Cancer Research offers a sweeping and authoritative ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

Results presented on Tuesday at the American Association for Cancer Reserch include data on the combined use of tissue and ...

Detection requires precision because most RNA circulating in the bloodstream originates from blood-forming cells rather than tumors. Rare tumor-derived RNA molecules are often masked by the ...

It can also detect cancer risk. This technology identifies changes in the immune system. It aids in precision ... amounts of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs ...

Encompass Health tapped Patrick Tuer to serve as its first COO. He has held various leadership positions, including group ...

Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022. Early detection plays a crucial role in reducing cancer-related morbidity ...